tirzepatide under the tongue TrimRX tirzepatide under the tongue Sublingual

In the trial, 18.2% of patients discontinued the high dose and 12.2% the lower dose due to adverse events, compared to the much lower 4% discontinuation rate in the placebo arm

Picking the wrong one doesn't just cause a denial

Keeping a symptom diary can help identify patterns and triggers, facilitating discussions with healthcare professionals about optimal management strategies

Starting weight loss treatment with QuickMD Effective obesity treatment is available now while we wait for future options like MariTide

The FDA approved Mounjaro in 2022 for managing type 2 diabetes, but its impact on weight loss is notable as well

doi:10.1159/000524281 Lean MEJ, et al